Survivin Antibody [HRP]

Western Blot: Survivin Antibody [HRP] [NB500-201H] -

Western Blot: Survivin Antibody [HRP] [NB500-201H] - sFZD7 sensitizes HCC cells to the anti-proliferative effect of doxorubicin in vivo. (A). Combination of sFZD7 & Doxil enhanced xenograft growth inhibition in vivo. Mice bearing Huh7-tumor xenografts were intratumorally injected weekly with PBS control; sFZD7 only (12.5 mg/kg); Doxil only (2.5 mg/kg); or sFZD7 (12.5 mg/kg) combined with Doxil (2.5 mg/kg) (n=5 in each treatment group). Tumor size was measured with digital calipers every three days. Significant differences in the tumor volumes between all treatment groups & the PBS control were observed after 14 days of treatment (*P < 0.05). Additionally, the sFZD7 plus Doxil combination group showed significant differences in tumor volumes compared with sFZD7 only or Doxil only groups after 17 days of treatment (*P < 0.05). (B). TUNEL staining of xenograft specimens removed from PBS control & all treatment groups (200 × magnification). Red arrows indicate some positively stained, apoptotic cells. (C). Representative cyclin D1 immunostaining of xenograft specimens removed from PBS control & all treatment groups are shown (200 × magnification). (D). Protein levels of c-Myc, cyclin D1, survivin, & beta -actin (loading control) in tumor xenografts from two mice in each group were determined by Western blotting using specific antibodies. (E). The expression levels of c-Myc, cyclin D1, survivin were determined by analyzing Western blots with the ImageJ software, & normalizing their signal intensities to beta -actin. Image collected & cropped by CiteAb from the following publication (https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-1…), licensed under a CC-BY license. Not internally tested by Novus Biologicals.